AIMS This project was designed to determine whether a coordinated regional strategy can improve the implementation of national guidelines for screening for retinopathy of prematurity (ROP), and to identify causes for failure of compliance.
METHODS Retrospective case note audit relating to two periods, 1990–1 and 1994, involving all 17 neonatal intensive care units in the Northern Region of England. Between the two periods, a regional strategy was instituted in an endeavour to improve compliance. Babies born in or admitted to the units during the study periods who were eligible for ROP screening were included. Screening performance was assessed against a standard of 100% compliance with the guidelines. In the second audit period compliance with subsidiary standards was also measured, and reasons for failure were identified.
RESULTS Compliance improved from 47% (262/558) in the first audit cycle to 73% (264/360) in the second. Subgroup analysis in this second cycle indicated better compliance (93.3%) in higher risk babies (⩽ 29 weeks' gestational age). Babies transferred between units, discharged home before screening, or who failed to qualify for screening on one of the two defined criteria, were more likely to be missed.
CONCLUSION A carefully implemented regional approach to screening resulted in a higher uptake for babies most at risk. Simple recommendations are made to achieve further improvement in compliance with the guidelines. The wider implications for screening in other conditions and in other areas and specialties are highlighted.
- retinopathy of prematurity
Statistics from Altmetric.com
Sight threatening retinopathy of prematurity (ROP) is a worldwide problem with a considerable geographical variation in its incidence,1-3 affecting 3.6% of babies born before 32 weeks' gestation in the Northern Region of the National Health Service in England (population approximately three million).4 The multicentre trial of cryotherapy treatment (CRYO-ROP) defined a threshold level of ROP at which treatment was to be administered; it resulted in a reduction of approximately 50% in the occurrence of posterior retinal traction, folds, and/or detachments.5Subsequent studies have shown diode laser treatment of ROP to be at least as effective as cryotherapy with fewer side effects.6
The goal of screening is to prevent unfavourable visual outcomes from ROP by detecting the more severe stages early enough to allow appropriate intervention. Protocols have been produced by national and international bodies to ensure that those babies at risk of blindness from ROP and reaching “threshold disease” are screened in time for treatment to be offered.7 “Threshold disease” is defined as stage 3 ROP involving 5 or more contiguous, or 8 or more cumulative, clock hours in zone 1 or 2 in the presence of congestion of the posterior pole vessels—“plus” disease. In the UK, national guidelines were produced in 1990 and revised in 1995.8They indicate that all babies born at ⩽31 weeks' gestation and/or ⩽1500 g birth weight should be screened from 6–7 weeks of postnatal age until there is vascularisation into zone 3. While there is currently some national and international debate about the need to screen all babies meeting these criteria,9 guidelines can only be effective if compliance with their recommendations is good.
The only study in the literature analysing compliance with guidelines for ROP screening comes from a single neonatal unit in North America.1011 The present study describes two separate audits of compliance with the national ROP screening guidelines8 for the Northern Region of England. Defects identified in the first audit cycle were addressed by a regional committee which met in 1993 and devised and implemented a regional strategy. In the second cycle the efficacy of this strategy was assessed and recommendations made for further improvement.
Materials and methods
Each audit cycle (cycle 1 and cycle 2) involved a retrospective review and analysis of case notes of babies eligible for ROP screening born in the Northern Region of England during the study periods. In each cycle the notes from all 17 neonatal units in the region were reviewed. The first period was 1990–1 (two full years) and the second period was 1994 (one full year).
Entry criteria were slightly different in the two cycles. The first audit formed part of a separate study of global outcomes of premature birth at age 2 years,4 involving all babies who were born before 32 weeks and survived to age 2 years. In the second cycle babies with a birth weight ⩽1500 g were also included (in order to follow the Royal College of Ophthalmologists' guidelines exactly)8 and the audit was performed on those who survived to screening age.
Standard A (cycles 1 and 2)
All babies satisfying the criteria in the guidelines should be screened.
Standard B (cycle 2 only)
Appropriate screening arrangements must be made for babies due to be transferred to another hospital or discharged home before the screening process is complete; this should include the receiving hospital being informed of the requirement for screening by the neonatal staff of the transferring hospital or, if the infant is discharged home, an appropriate outpatient appointment must be made. After the first cycle a regional strategy for screening was circulated to all 17 neonatal units, to ophthalmologists, to paediatricians in the region, and to those responsible for regional health policy. The strategy document reiterated the guidelines, indicated that the attending paediatrician was responsible for identifying babies requiring screening, and specified a named ophthalmologist to provide screening for each neonatal unit. Additional arrangements were included in case the named ophthalmologist should be unavailable. Three ophthalmic specialists in the region were identified as being available to provide advice on screening to colleagues, and to offer a prompt treatment service for babies identified as having threshold disease. The importance of communication of screening requirements on discharge or transfer to another hospital was emphasised.
The case notes were scrutinised for evidence of adherence to these standards. In cycle 2, additional data on factors associated with compliance or non-compliance with the standards were sought. “High risk” babies were defined as those born at 29 weeks' gestation or less.413
In all, 565 babies were eligible for inclusion in cycle 1; case notes were available for 558 babies (98.8%). A total of 367 babies were eligible and 360 case notes were available (98.1%), in cycle 2.
AUDIT STANDARD A
Basic screening compliance
Compliance improved from 47% (262 out of 558 babies) in the first cycle to 73% (264 out of 360 babies) in the second cycle.
Compliance figures in cycle 2
Compliance rates in cycle 2 were analysed for groups subdivided into ranges of gestational age at birth (GA) and birth weight (BW). Figure 1 shows the number of premature babies screened in the different GA groups; 93% (140 of 150) of “high risk” babies (GA ⩽29 weeks) were screened. Screening failures occurred more frequently in babies who did not fulfil one of the two entry criteria (Table1).
AUDIT STANDARD B
Of the 264 screened babies the guidelines were followed rigidly in only 183 (70%). In 75 (28%) the screening did not accurately follow the guidelines, being started late in 51, finished early in 11, and otherwise inadequate in 13.
A total of 72 out of the 264 (27%) babies screened developed ROP; 38 reached stage 1 ROP, 15 reached stage 2 ROP, and 19 reached stage 3 ROP.13 Of those with stage 3, 15 reached threshold disease and were treated by cryotherapy to the avascular retina.
A total of 196 babies were transferred to a different neonatal unit before completion of screening. Screening was mentioned in the transfer letter in only 87 (44%) and data were unavailable in 12 (6%). Screening was completed in 83 (95%) of those transferred with such a letter. In those transferred without a recommendation letter for screening only 73 (75%) were screened for ROP. Ten of the transferred babies (5.1%) developed stage 3 ROP, a virtually identical percentage to that of non-transferred babies (5.5%). However, five of the 14 babies (36%) who were transferred three or more times developed threshold stage 3 disease; all of these were under 27 weeks' gestation and under 850 g at birth. Three of these 14 babies (21%) were never screened, but all three were born at 30 or more weeks' gestation and were over 1300 g.
In all, 71 babies were discharged home before 36 weeks of postmenstrual age. In 57 cases (80.3%) the discharge summary gave no indication of arrangements for screening and none was screened after discharge. In the remaining 14 cases, an appointment was made before discharge or there was a request for screening in the discharge summary. Of these, nine babies were screened and the others either failed to attend to the clinic (three) or no follow up appointment was sent to them (two).
Treatment of acute ROP reduces the incidence of retinal scarring and detachment with a consequent reduction in subsequent visual handicap.5 Surgical treatment of retinal detachment due to ROP, while achieving some anatomical success, results in minimal if any visual improvement.14 It is important therefore that premature infants with threshold disease are identified and treated before irretrievable damage occurs. The interval between threshold being reached and detachment occurring may only be a matter of days so for the screening programme to succeed it must be effectively implemented. Only one study in the literature has addressed this.1011
The low compliance rate in cycle 1 indicated that arrangements for screening were haphazard and unreliable. Our study therefore addressed the identification of premature infants at risk of acute ROP and the potential benefits of a coordinated regional strategy. A retrospective design was chosen to avoid the possibility that a prospective study would alert personnel to the requirement to screen for ROP, potentially only for the duration of the study, and therefore would not allow accurate assessment of the effects of the strategy.11
There are systematic differences between cycle 1 and cycle 2: cycle 1 did not include babies who were >31 weeks but ⩽1500 g and excluded those babies who died before 2 years of age; cycle 2 included the birthweight criterion and all babies who survived long enough to be screened. Reanalysis of cycle 2 without the birthweight criterion increases the screening rate from 73% to 80% and magnifies the difference between the two cycles. Data from regional records indicate that 31 additional babies would have been included in cycle 1 had they not died between screening age and 2 years, and these babies might have been at higher risk of ROP and more likely to have been screened. However, even if compliance with screening were 100% in these cases, the overall compliance for cycle 1 would increase only marginally (to 50%), which would not make a significant difference to the result.
This study indicates that there was a large improvement (from 47% to 73%) in the ROP screening rate throughout the region following implementation of a regional strategy. Screening failures in cycle 2 were largely confined to low risk >29 week babies and those who failed to meet one of the screening criteria; no significant sequelae of acute ROP had subsequently been recorded in any of these cases when the case note review was performed (1996–7). The results indicate, however, that babies transferred to other hospitals are at particular risk of being missed from screening unless clear recommendations are made to the receiving unit and a mechanism exists to put these into effect. The high percentage (36%) of babies undergoing multiple transfer who developed threshold stage 3 ROP is interesting; fortunately they were all of very early gestation and therefore unlikely to be missed from screening.
It cannot be proved that the strategy was the sole cause of the improvement as general awareness of ROP has been increasing over this time but we believe that the availability of a named ophthalmologist to paediatricians in every neonatal unit has been central to its success. It was also helpful that the strategy identified the professional responsible for initiating the screening process in each individual case (the paediatrician).
Ophthalmological review did not continue in some instances for as long as the guidelines recommend. It is not clear from this study whether this was due to rapid retinal maturation (positive identification of the lack of clinical need for further examinations) or to administrative or other problems. Screening is sometimes postponed because the baby is judged to be too sick to tolerate the stress although it was not possible positively to identify this as a reason from a retrospective notes review. This could have important medicolegal implications.
Further recommendations have been made within the region since the results of cycle 2 became available:
Neonatal units are encouraged to keep a diary for prospective entry of dates for ROP screening to begin.
Standard templates for discharge/transfer letters should contain a default section on ROP screening.
A standard screening record form, the design of which has been agreed throughout the region, should always be used.
When screening is incomplete at the time of transfer, copies of the screening records to date should be faxed to the ophthalmologist responsible for the receiving unit.
Where postponement or early termination of screening occurs this should be positively identified in the case notes.
A third audit is planned in due course.
The data here relate to a single health region in the UK but the measures taken or recommended are simple in themselves and could readily be adopted and applied in other areas in order to improve compliance.
Presented at World ROP Meeting, Taormina, Sicily, Italy in September 1997 and at the Royal College of Ophthalmologists Audit Day “Audit at the Cutting Edge” May 1998.
Thanks to the Northern Neonatal Network team who helped with notes retrieval and to the Northern Regional Purchaser Clinical Audit Group who funded the project. The authors are also grateful to their many colleagues who allowed their patients' records to be studied.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.